Android app on Google Play

Benchmark Downgrades CryoLife (CRY) to Hold

August 6, 2012 7:25 AM EDT Send to a Friend
Get Alerts CRY Hot Sheet
Price: $9.89 +0.82%

Rating Summary:
    1 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 18 | Down: 9 | New: 22
Trade CRY Now!
Join SI Premium – FREE
Benchmark downgraded CryoLife (NYSE: CRY) from Buy to Hold with a price target of $6.00 (from $7.50).

Analyst Raymond Myers said "We are lowering our rating to Hold following Q2 results as PerClot’s FDA clinical trial enrollment was delayed from mid-2012 to early 2013. We believe this shift is benefiting 2012 results through lower R&D expenditure, at the expense of 2013. We now forecast meaningful earnings expansion beginning in 2014. Our lowered $6.00 price target is 20x $0.37 EPS in 2014, discounted one year at 25%, plus $0.34 per share in cash."

For an analyst ratings summary and ratings history on CryoLife click here. For more ratings news on CryoLife click here.

Shares of CryoLife closed at $5.21 yesterday.




You May Also Be Interested In


Related Categories

Downgrades

Related Entities

Earnings

Add Your Comment